Patients above Sixty Years Lymphoma Treated with a New Strategy of Age with Hodgkin's

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

“…CR rates published for older patients with HL range between 49% and 77% for mechlorethamine (Mustargen), vincristine (Oncovin), procarbazine, prednisone (MOPP), MOPP/ABVD, BEACOPP baseline, and COPP/ABVD-like regimens. 12,19,29,30 Thus, the CR rate for BACOPP of 85% compares favorably with other regimens reported. The outcome was not associated with stage or IPS, although these results might be humbled by the small sample size.…”

“…13,18,19,27,30 Today, ABVD has replaced most of these regimens and is being regarded as standard of care. This is in part based on the work of Canellos et al 31 who demonstrated a similar efficacy and lower myelotoxicity for ABVD than for MOPP or MOPP/ABVD.…”

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study

“…10 In the 1990s and early 2000s, a small number of retrospective studies of older HL patients were reported. 13,[15][16][17] The common findings were as follows: delivering chemotherapy is difficult in this cohort; complications of chemotherapy, including septic death, are more common than in younger patients; response rates and OS are unsatisfactory and inconsistent between studies, particularly for patients with advanced-stage disease. Such studies did not define a way forward.…”

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

“…Enblad et al, analyzing registry data from 1985 through 1992 for eHL, showed that the IPS did not independently predict outcome. 17 On multivariate regression analysis, only 2 factors here were associated with inferior outcomes: (1) age more than or equal to 70 years (PFS: hazard ratio ϭ 1.76, 95% CI, 0.98-3.16, P ϭ .06; and OS: hazard ratio ϭ 2.24, 95% CI, 1.16-4.33, P ϭ .02); and (2) loss of ADLs (PFS: hazard ratio ϭ 2.47, 95% CI, 0.98-6.21, P ϭ .055; and OS: hazard ratio ϭ 2.71, 95% CI, 1.07-6.84, P ϭ .04; supplemental Table 1). Furthermore, these factors remained significant with the 5 subjects with lymphocyte predominant histology excluded (supplemental Tables 2-3).…”